Back to Search Start Over

Current treatment of HER 2+ metastatic breast cancer.

Authors :
Burcombe, Russell
Source :
British Journal of Nursing; 2017 Supplement 16a, Vol. 26, pS7-S14, 1p
Publication Year :
2017

Abstract

Historically, HER2-positive breast cancer had a poor prognosis. The development of molecul ar ther apies that target the HER2 receptor has TR ansformed outcomes. Here, the evidence on Anti-HER2 therapies is summarised [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
BREAST cancer treatment
METASTASIS
ANTINEOPLASTIC agents
THERAPEUTIC use of monoclonal antibodies
PROTEIN-tyrosine kinase inhibitors
TRASTUZUMAB
DOCETAXEL
AROMATASE inhibitors
ANASTROZOLE
BREAST tumors
CANCER chemotherapy
IMMUNOHISTOCHEMISTRY
ONCOGENES
SURVIVAL analysis (Biometry)
FLUORESCENCE in situ hybridization
THERAPEUTICS

Details

Language :
English
ISSN :
09660461
Volume :
26
Database :
Complementary Index
Journal :
British Journal of Nursing
Publication Type :
Academic Journal
Accession number :
132098255
Full Text :
https://doi.org/10.12968/bjon.2017.26.Sup16a.S7
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details